BR112023020348A2 - Regimes de dosagem de ceftibuteno - Google Patents

Regimes de dosagem de ceftibuteno

Info

Publication number
BR112023020348A2
BR112023020348A2 BR112023020348A BR112023020348A BR112023020348A2 BR 112023020348 A2 BR112023020348 A2 BR 112023020348A2 BR 112023020348 A BR112023020348 A BR 112023020348A BR 112023020348 A BR112023020348 A BR 112023020348A BR 112023020348 A2 BR112023020348 A2 BR 112023020348A2
Authority
BR
Brazil
Prior art keywords
ceftibutene
ceftibuten
dosage regimes
twice daily
daily
Prior art date
Application number
BR112023020348A
Other languages
English (en)
Inventor
c griffith David
e morgan Elizabeth
S LOUTIT Jeffery
Olga Lomovskaya
Original Assignee
Qpex Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma Inc filed Critical Qpex Biopharma Inc
Publication of BR112023020348A2 publication Critical patent/BR112023020348A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

regime6 de dosagem de ceftibuteno. são descritos, no presente documento, regimes de dosagem de ceftibuteno em combinação com um inibidor de ß-lactamase. os regimes de dosagem incluem ceftibuteno em uma dose maior do que 400 mg por dia (por exemplo, 400 mg duas vezes ao dia, 600 mg uma vez ao dia ou duas vezes ao dia, ou 800 mg uma vez ao dia ou duas vezes ao dia).
BR112023020348A 2021-04-05 2022-03-31 Regimes de dosagem de ceftibuteno BR112023020348A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170936P 2021-04-05 2021-04-05
PCT/US2022/071479 WO2022217199A1 (en) 2021-04-05 2022-03-31 Ceftibuten dosing regimens

Publications (1)

Publication Number Publication Date
BR112023020348A2 true BR112023020348A2 (pt) 2023-11-21

Family

ID=83545863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020348A BR112023020348A2 (pt) 2021-04-05 2022-03-31 Regimes de dosagem de ceftibuteno

Country Status (11)

Country Link
US (1) US20240197750A1 (pt)
EP (1) EP4319760A1 (pt)
JP (1) JP2024512793A (pt)
KR (1) KR20230167077A (pt)
CN (1) CN117157078A (pt)
AU (1) AU2022254114A1 (pt)
BR (1) BR112023020348A2 (pt)
CA (1) CA3212788A1 (pt)
MX (1) MX2023011483A (pt)
TW (1) TW202304430A (pt)
WO (1) WO2022217199A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252351A1 (en) * 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
ES2894251T3 (es) * 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
SG11201811345TA (en) * 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
LT3512851T (lt) * 2016-09-16 2022-10-25 Entasis Therapeutics Limited Beta-laktamazės inhibitorių junginiai
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
WO2020112542A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
KR20220054364A (ko) * 2019-08-29 2022-05-02 아릭사 파마슈티컬스 인코포레이티드 박테리아 감염을 치료하기 위해 경구 투여되는 베타-락탐 항생제 및 아비박탐 유도체의 조합

Also Published As

Publication number Publication date
TW202304430A (zh) 2023-02-01
WO2022217199A1 (en) 2022-10-13
AU2022254114A1 (en) 2023-09-21
CA3212788A1 (en) 2022-10-13
CN117157078A (zh) 2023-12-01
US20240197750A1 (en) 2024-06-20
JP2024512793A (ja) 2024-03-19
KR20230167077A (ko) 2023-12-07
MX2023011483A (es) 2023-10-03
EP4319760A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
Weiss et al. Crystalloid fluid choice and clinical outcomes in pediatric sepsis: a matched retrospective cohort study
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
Claeys et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections
Zisook et al. Use of bupropion in combination with serotonin reuptake inhibitors
BR112012030625A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
BR112016007479A2 (pt) regimes de dosagem de imunoconjugado de anti-folr1
Boianelli et al. Oseltamivir PK/PD modeling and simulation to evaluate treatment strategies against influenza-pneumococcus coinfection
BR112018002550A2 (pt) mecanismo de resistência a inibidores do bromodomínio de bet
Smith et al. High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it
BR112022026202A2 (pt) Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
BR112021008582A8 (pt) Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
Wagner et al. Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder
BR112023020348A2 (pt) Regimes de dosagem de ceftibuteno
Toyama et al. A randomized phase II study evaluating pyridoxine for the prevention of hand–foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer
Kasper et al. Superiority of escitalopram to paroxetine in the treatment of depression
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
BRPI0716929A8 (pt) tratamento de esclerose múltipla com campath-1h
NO20070763L (no) Kombinasjonsterapi med radiomerket anti-CD20-antistoff i behandlingen av B-cellelymfom
BR112022004670A2 (pt) Dispositivo de computação e método implementado por computador
BR112020013750A8 (pt) Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
PH12021551137A1 (en) Application of chidamide
BR112022024533A2 (pt) Formulação compreendendo daprodustat
Li et al. Influenza in hospitalised patients with malignancy: a propensity score matching analysis